Advances of NSABP breast cancer trails in the past decade

Abstract

Abstract:The research findings published by National Surgical Adjuvant Breast and Bowel Project have continued to change the clinical practice of earlystage breast cancer over the past decade. Sentinel lymph node biopsy has become the new surgical operation standard. The aromatase inhibitor adjuvant endocrine therapy cycle has been extended from 5 years to 10 years, which benefits the patients with high risk and reactivity. Chemotherapy combined with trastuzumab has become the standard adjuvant therapy strategy of human epidermal growth factor receptor 2 positive invasive breast cancer. In addition, the research progress is also related to the optimization of the fields including the postoperative adjuvant chemotherapy and neoadjuvant chemotherapy.

Key words:Breast neoplasms,Surgical procedures,Adjuvant therapy

Huang Jiefeng, Lin Xiaorong, Wu Zhiyong. Advances of NSABP breast cancer trails in the past decade[J]. Journal of International Oncology, 2017, 44(7): 547-549.

References

［1］ Krag DN, Anderson SJ, Julian TB, et al. Sentinellymphnode resection compared with conventional axillarylymphnode dissection in clinically nodenegative patients with breast cancer: overall survival findings from the NSABP B32 randomised phase 3 trial［J］. Lancet Oncol, 2010, 11(10): 927-933. DOI: 10.1016/S14702045(10)702072. ［2］ Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer［J］. N Engl J Med, 2010, 362(22): 2053-2065. DOI: 10.1056/NEJMoa0909638. ［3］ Swain SM, Tang G, Geyer CE, et al. Definitive results of a phase Ⅲ adjuvant trial comparing three chemotherapy regimens in women with operable, nodepositive breast cancer: the NSABP B38 trial［J］. J Clin Oncol, 2013, 31(26): 3197-3204. DOI: 10.1200/JCO.2012.48.1275. ［4］ Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intentiontotreat analysis of the National Surgical Adjuvant Breast and Bowel Project B33 trial［J］. J Clin Oncol, 2008, 26(12): 19651971. DOI: 10.1200/JCO.2007.14.0228. ［5］ Mamounas EP, Lembersky B, Jeong J, et al. NSABP B42: A clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging diseasefree survival in postmenopausal women with hormone receptorpositive breast cancer［J］. Clin Breast Cancer, 2006, 7(5): 416421. DOI: 10.3816/CBC.2006.n.061. ［6］ Wapnir IL, Dignam JJ, Fisher B, et al. Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS［J］. J Natl Cancer Inst, 2011, 103(6): 478488. DOI: 10.1093/jnci/djr027. ［7］ Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, doubleblind, phase 3 clinical trial［J］. Lancet, 2016, 387(121): 849-856. DOI: 10.1016/S0140-6736(15)01168-X. ［8］ Siziopikou KP, Anderson SJ, Cobleigh MA, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B43［J］. Breast Cancer Res Treat, 2013, 142(2): 415-421. DOI: 10.1007/s10549-013-2755-z. ［9］ Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831［J］. J Clin Oncol, 2014, 32(33): 3744-3752. DOI: 10.1200/JCO.2014.55.5730. ［10］ Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B40 ［NRG Oncology］): secondary outcomes of a phase 3, randomised controlled trial［J］. Lancet Oncol, 2015, 16(9): 1037-1048. DOI: 10.1016/S1470-2045(15)00041-8. ［11］ Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2positive operable breast cancer (NSABP protocol B41): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1183-1192. DOI: 10.1016/S1470-2045(13)70411-X.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[12]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Xu Fang, Zhu Wentian.Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion[J]. Journal of International Oncology, 2023, 50(5): 304-309.
[15]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.